These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 27999600)

  • 21. Generation of mesenchymal stem cells as a medicinal product in organ transplantation.
    Verbeek R
    Curr Opin Organ Transplant; 2013 Feb; 18(1):65-70. PubMed ID: 23222173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A short-term plastic adherence incubation of the stromal vascular fraction leads to a predictable GMP-compliant cell-product.
    Born S; Dörfel MJ; Hartjen P; Haschemi Yekani SA; Luecke J; Meutsch JK; Westphal JK; Birkelbach M; Köhnke R; Smeets R; Krueger M
    Bioimpacts; 2019; 9(3):161-172. PubMed ID: 31508331
    [No Abstract]   [Full Text] [Related]  

  • 23. Ex vivo-expanded highly pure ABCB5
    Kerstan A; Niebergall-Roth E; Esterlechner J; Schröder HM; Gasser M; Waaga-Gasser AM; Goebeler M; Rak K; Schrüfer P; Endres S; Hagenbusch P; Kraft K; Dieter K; Ballikaya S; Stemler N; Sadeghi S; Tappenbeck N; Murphy GF; Orgill DP; Frank NY; Ganss C; Scharffetter-Kochanek K; Frank MH; Kluth MA
    Cytotherapy; 2021 Feb; 23(2):165-175. PubMed ID: 33011075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GMP-Compatible, Xeno-Free Culture of Human Induced Mesenchymal Stem Cells.
    de Peppo GM
    Methods Mol Biol; 2021; 2286():121-129. PubMed ID: 33381853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Production of mesenchymal stromal/stem cells according to good manufacturing practices: a review.
    Sensebé L; Gadelorge M; Fleury-Cappellesso S
    Stem Cell Res Ther; 2013 Jun; 4(3):66. PubMed ID: 23751270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GMP-conformant on-site manufacturing of a CD133
    Skorska A; Müller P; Gaebel R; Große J; Lemcke H; Lux CA; Bastian M; Hausburg F; Zarniko N; Bubritzki S; Ruch U; Tiedemann G; David R; Steinhoff G
    Stem Cell Res Ther; 2017 Feb; 8(1):33. PubMed ID: 28187777
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization and cost-benefit analysis of automated bioreactor-expanded mesenchymal stem cells for clinical applications.
    Russell AL; Lefavor RC; Zubair AC
    Transfusion; 2018 Oct; 58(10):2374-2382. PubMed ID: 30203447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current Status of PRP Manufacturing Requirements & European Regulatory Frameworks: Practical Tools for the Appropriate Implementation of PRP Therapies in Musculoskeletal Regenerative Medicine.
    Sebbagh P; Cannone A; Gremion G; Gremeaux V; Raffoul W; Hirt-Burri N; Michetti M; Abdel-Sayed P; Laurent A; Wardé N; Applegate LA
    Bioengineering (Basel); 2023 Feb; 10(3):. PubMed ID: 36978683
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current regenerative medicine-based approaches for skin regeneration: A review of literature and a report on clinical applications in Japan.
    Shimizu Y; Ntege EH; Sunami H
    Regen Ther; 2022 Dec; 21():73-80. PubMed ID: 35785041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulatory-compliant conditions during cell product manufacturing enhance in vitro immunomodulatory properties of infrapatellar fat pad-derived mesenchymal stem/stromal cells.
    Kouroupis D; Bowles AC; Greif DN; Leñero C; Best TM; Kaplan LD; Correa D
    Cytotherapy; 2020 Nov; 22(11):677-689. PubMed ID: 32723596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Isolation and prolonged expansion of oral mesenchymal stem cells under clinical-grade, GMP-compliant conditions differentially affects "stemness" properties.
    Bakopoulou A; Apatzidou D; Aggelidou E; Gousopoulou E; Leyhausen G; Volk J; Kritis A; Koidis P; Geurtsen W
    Stem Cell Res Ther; 2017 Nov; 8(1):247. PubMed ID: 29096714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Responsible, Safe, and Effective Use of Biologics in the Management of Low Back Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines.
    Navani A; Manchikanti L; Albers SL; Latchaw RE; Sanapati J; Kaye AD; Atluri S; Jordan S; Gupta A; Cedeno D; Vallejo A; Fellows B; Knezevic NN; Pappolla M; Diwan S; Trescot AM; Soin A; Kaye AM; Aydin SM; Calodney AK; Candido KD; Bakshi S; Benyamin RM; Vallejo R; Watanabe A; Beall D; Stitik TP; Foye PM; Helander EM; Hirsch JA
    Pain Physician; 2019 Jan; 22(1S):S1-S74. PubMed ID: 30717500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adult mesenchymal stem cells and their exosomes: Sources, characteristics, and application in regenerative medicine.
    Maqsood M; Kang M; Wu X; Chen J; Teng L; Qiu L
    Life Sci; 2020 Sep; 256():118002. PubMed ID: 32585248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a human umbilical cord-derived mesenchymal stromal cell-based advanced therapy medicinal product to treat immune and/or inflammatory diseases.
    Mebarki M; Iglicki N; Marigny C; Abadie C; Nicolet C; Churlaud G; Maheux C; Boucher H; Monsel A; Menasché P; Larghero J; Faivre L; Cras A
    Stem Cell Res Ther; 2021 Nov; 12(1):571. PubMed ID: 34774107
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A practical approach for gmp-compliant validation of real-time PCR method for mycoplasma detection in human mesenchymal stromal cells as advanced therapy medicinal product.
    Becherucci V; Curini L; Ceccantini R; Bisin S; Gori V; Gentile F; De Rienzo E; Piccini L; Bindi B; Pavan P; Cunial V; Allegro E; Ermini S; Brugnolo F; Bambi F
    Biologicals; 2021 Sep; 73():31-40. PubMed ID: 34362616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GMP-grade human fetal liver-derived mesenchymal stem cells for clinical transplantation.
    Larijani B; Aghayan HR; Goodarzi P; Arjmand B
    Methods Mol Biol; 2015; 1283():123-36. PubMed ID: 25092054
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Good Manufacturing Practice (GMP) Translation of Advanced Cellular Therapeutics: Lessons for the Manufacture of Erythrocytes as Medicinal Products.
    McGowan NWA; Campbell JDM; Mountford JC
    Methods Mol Biol; 2018; 1698():285-292. PubMed ID: 29076098
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GMP-Compliant Production of Human Placenta-Derived Mesenchymal Stem Cells.
    Aghayan HR; Payab M; Mohamadi-Jahani F; Aghayan SS; Larijani B; Arjmand B
    Methods Mol Biol; 2021; 2286():213-225. PubMed ID: 32504292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. hiPSC-derived iMSCs: NextGen MSCs as an advanced therapeutically active cell resource for regenerative medicine.
    Sabapathy V; Kumar S
    J Cell Mol Med; 2016 Aug; 20(8):1571-88. PubMed ID: 27097531
    [TBL] [Abstract][Full Text] [Related]  

  • 40. GMP facilities for manufacturing of advanced therapy medicinal products for clinical trials: an overview for clinical researchers.
    Alici E; Blomberg P
    Curr Gene Ther; 2010 Dec; 10(6):508-15. PubMed ID: 21054243
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.